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Current Ebola virus disease (EVD) diagnosis relies on 
reverse transcription-PCR (RT-PCR) technology, requir-
ing skilled laboratory personnel and technical infra-
structure. Lack of laboratory diagnostic capacity has 
led to diagnostic delays in the current West African 
EVD outbreak of 2014 and 2015, compromising out-
break control. We evaluated the diagnostic accuracy 
of the EVD bedside rapid diagnostic antigen test (RDT) 
developed by the United Kingdom’s Defence Science 
and Technology Laboratory, compared with Ebola virus 
RT-PCR, in an operational setting for EVD diagnosis of 
suspected cases admitted to Ebola holding units in 
the Western Area of Sierra Leone. From 22 January 
to 16 February 2015, 138 participants were enrolled. 
EVD prevalence was 11.5%. All EVD cases were iden-
tified by a positive RDT with a test line score of 6 or 
more, giving a sensitivity of 100% (95% confidence 
interval (CI): 78.2–100). The corresponding specificity 
was high (96.6%, 95% CI: 91.3–99.1). The positive and 
negative predictive values for the population preva-
lence were 79.0% (95% CI: 54.4–93.8) and 100% (95% 
CI: 96.7–100), respectively. These results, if confirmed 
in a larger study, suggest that this RDT could be used 
as a ‘rule-out’ screening test for EVD to improve rapid 
case identification and resource allocation.
Introduction
than one year after the first human-to-human transmis-
sion, the largest Ebola virus disease (EVD) outbreak 
continues in West Africa, with an estimated 24,701 
cases reported and 10,194 deaths by 15 March 2015 
[1]. To date, Sierra Leone is the most severely affected 
country.
Case identification is essential for effective EVD control 
and rapid case detection is critical for rationalisation 
of resources and implementation of early treatment 
interventions [2]. A locally adapted EVD clinical case 
definition allows suspected cases to be identified and 
isolated in Ebola holding units (EHU), but this alone 
is inadequate to reliably differentiate EVD cases from 
patients with other conditions that mimic EVD presen-
tation [3]. A confirmed EVD diagnosis is a prerequisite 
for transfer of a patient to an EVD treatment centre 
(ETC) to access EVD-specific care. All patients meeting 
the suspected case definition require isolation, labora-
tory sampling and diagnostic testing. For such patients, 
a negative EVD result is required before admission into 
general healthcare. 
Current EVD diagnosis relies on reverse transcription-
PCR (RT-PCR) technology [4]. This test is highly sensitive 
and specific but requires skilled laboratory personnel 
and technical infrastructure [5]. In the early months 
of the current West African outbreak, these person-
nel and infrastructure were largely absent locally. As 
the EVD response has grown, laboratory infrastruc-
ture in the region has improved, but this may not be 
sustainable in the long term or available at the onset 
of future outbreaks. In addition, the current EVD diag-
nostic pathway has cost, resource and safety implica-
tions relating to venous blood sampling inside the EHU, 
timely transport of samples to the EVD diagnostic labo-
ratory, potential for labelling error, and rapid relay of 
results [6].
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One immunofiltration antigen-based assay developed 
in the mid-2000s has been tested on field specimens 
from 2003, but is not yet available in routine clinical 
practice and requires a photometer for analysis [7].
A rapid diagnostic test for EVD, performed at the bed-
side in EHUs or other isolation facilities would be of 
great benefit [8]. The Defence Science and Technology 
Laboratory (DSTL) in the United Kingdom (UK) has 
developed a rapid antigen diagnostic test (RDT) for EVD 
diagnosis. The DSTL EVD RDT is a bedside lateral flow 
assay using capillary blood rather than venous blood 
to detect presence of an undisclosed Ebola virus anti-
gen. The test can be conducted and interpreted with 
minimal training and the result is obtained within 20 
min. A semi-quantitative result is obtained by scoring a 
test line on colour intensity.
In this study, we evaluate the diagnostic accuracy of 
the DSTL EVD RDT compared with the gold standard 
Ebola virus (EBOV) RT-PCR in an operational setting 
for EVD diagnosis of suspected EVD cases admitted to 
EHUs in the Western Area of Sierra Leone.
Methods
The study was conducted at four EHUs in the Western 
Area of Sierra Leone that routinely isolated suspected 
EVD cases and collected diagnostic blood samples 
for EVD testing: Connaught Government Hospital 
(the national adult referral hospital), Macauley Street 
Government Hospital, Rokupa Government Hospital, 
and Newton Health Centre. These sites belong to a net-
work of holding units supported by King’s Sierra Leone 
Partnership (KSLP) and managed by the Ministry of 
Health and Sanitation (MOHS) and use a screening tool 
based on the national case definition for suspected 
EVD cases, combining exposure risk evaluation and a 
symptom checklist for identification of suspected EVD 
cases. Each centre had trained phlebotomists and local 
healthcare workers who routinely provided patient 
care. Clinical staff were invited to training in the use 
of the RDT and study protocol which was undertaken in 
three one-hour sessions.
Staff who completed the training were approved to 
enrol patients and perform the RDT. Trained clinical 
staff obtained verbal informed consent from consecu-
tive patients newly admitted to the EHU during the 
study period, wearing appropriate personal protective 
equipment [9]. Patients who could not give informed 
consent (e.g. due to young age, cognitive impairment 
or confusion) and patients who withheld consent were 
not enrolled.
Enrolment occurred on the day of admission or on the 
following day when patients were admitted during 
the night. In all cases, enrolment occurred before the 
results of routine EVD diagnostic testing were avail-
able, i.e. only suspected cases were enrolled. The RDT 
was performed at the bedside. All equipment for the 
RDT was provided in individually packaged test kits. 
Capillary blood for the RDT was obtained using a sterile 
lancet to prick a finger. Blood was applied to the well 
of the lateral flow device with a small pipette, followed 
by three drops of buffer. After 20 min, the RDTs were 
read in designated areas with good lighting and scores 
were obtained with the aid of a scorecard. RDTs were 
scored C when a single control (C) line was visible and 
CT when the C line and the test (T) line were visible. If 
visible, the T line was scored [2-10] on colour intensity 
by matching the T line to samples on the scorecard. 
Clinical staff performing RDTs were blind to RDT score 
interpretation.
Venepuncture for routine EVD diagnostic testing was 
performed as per routine clinical care, usually on the 
same day as the RDT. Venous blood samples were 
transported to the Public Health England (PHE) labora-
tory at Port Loko for EVD RT-PCR testing with the Altona 
RealStar Filovirus screen kit for real-time PCR (Altona 
Diagnostics Gmbh, Germany). Extraction was per-
formed using a manual method with the Qiagen QIAamp 
Viral RNA kit (Qiagen). Altona quote a detection limit of 
1.39 copies/µL of eluate (range: 0.69 to 5.32) for Zaire 
EBOV and 100% specificity against a range of viruses. 
In a small number of cases, routine EVD diagnostic 
testing by RT-PCR on venous blood was performed at 
other local diagnostic laboratories. Laboratory person-
nel were blind to the RDT result. The Altona assay has 
been selected by the World Health Organization (WHO) 
as the reference standard for this outbreak.
Study enrolment and results were recorded in a pass-
word protected spreadsheet and matched to EVD 
RT-PCR results for analysis by the study coordinator 
(NFW). Analysis was performed in Excel (Microsoft 
Corporation), Prism 6 (GraphPad Software, Inc), and 
Medcalc version 15.2.2 (Medcalc Software, Ostend 
Belgium). As the DSTL EVD RDT provides a quantitative 
result, analysis was performed to establish the diag-
nostic accuracy of the test for the range of CT scores, in 
comparison with the gold standard result. Results were 
anonymised before dissemination. Reporting of results 
follows the STARD (Standards for Reporting Diagnostic 
Accuracy Studies) statement [10].
The study was approved by the Sierra Leone Ethics and 
Scientific Review Committee (SLESRC, 16/01/2015).
Results
Participants and enrolment
Participants were recruited consecutively at study 
sites, from 22 January to 16 February 2015. A total of 
138 participants were enrolled. At Connaught Hospital, 
112 patients were enrolled. This constituted 83% of 
135 total admissions at Connaught Hospital EHU dur-
ing the study period. Seven enrolled participants were 
excluded at the analysis stage because insufficient 
information was available (Figure 1). Of these patients, 
four had RDT tests performed but did not have corre-
sponding EVD RT-PCR results available. The RDT result 
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was negative in each of these cases. One patient had 
a negative EVD RT-PCR result but did not have an RDT 
result recorded. One patient had neither RDT nor EVD 
RT-PCR result available. One patient with a negative 
RDT had no corresponding EVD RT-PCR result available 
but similar clinical details to a subsequent participant, 
suggesting that this was an error in documentation and 
possibly a double entry. Finally, 131 participants were 
included in the analysis. Of those, 90 (68.7%) were 
male, and the median age was 32 years (interquartile 
range (IQR): 24–47 years).
Ebola virus disease diagnosis
Fifteen of 131 patients tested positive for EVD by EVD 
RT-PCR, giving a study EVD prevalence of 11.5% (Figure 
2). Data on duration of symptoms before presentation 
for EVD-positive patients was available for seven of 15 
(47%) cases. In these patients, median symptom dura-
tion before date of EVD diagnostic testing was four 
days (IQR: 3–5 days). The PHE Port Loko laboratory 
processed 125 of the laboratory samples (95%). Three 
samples were processed at the PHE Kerry Town labo-
ratory using the same diagnostic assay and standard 
operating procedure as PHE Port Loko, and three sam-
ples were processed at other laboratories.
Performance of the rapid diagnostic antigen 
test 
Twenty-four patients had RDT results with both C and 
T line visible (CT). In 15 of these patients, an EVD diag-
nosis was made by positive EVD RT-PCR and in nine 
cases, EVD RT-PCR results were negative (Table 1). In 
all confirmed cases of EVD, a T line was present on the 
RDT (Table 1 and Figure 3). Higher CT scores were found 
in patients with EVD than those without EVD (Table 1 
and Figure 3).
Table 2 details the sensitivity and specificity of the 
RDT with increasing CT score. If any test with a visible 
T line (corresponding to CT score of CT2 and above) 
was classified as positive, the RDT had a sensitivity of 
100% (95% confidence interval (CI): 78.2–100) and a 
specificity of 92% (95% CI: 85.8–96.4) compared with 
the gold standard RT-PCR. If any test with a T line score 
above 4 (corresponding to a CT score of CT6 and above) 
was classified as positive, the RDT remained 100% sen-
sitive (95% CI: 78.2–100), but had a higher specificity 
of 97% (95% CI: 91.4–99.1). The specificity of the test 
increased with higher CT score threshold for a positive 
result, but the corresponding sensitivity was reduced 
DSTL: Defence Science and Technology Laboratory; RDT: rapid 
diagnostic antigen test.
a  In one case the RDT  attempt failed as an extremely small 
volume of blood was collected after the pinprick, in a second 
case no RDT result was documented.
b  Possible double entry of a patient with discordant RDT results
Figure 1
DSTL rapid diagnostic antigen test for Ebola virus disease, 
study enrolment and inclusion, Sierra Leone, January–
February 2015 (n = 138)
138 enrolled
 
136 RDT results 
available  
2 RDT results  not  availablea 
132 laboratory 
results available  
4 without 
available 
corresponding 
laboratory result 
131 included
 
 
in analysis
 
1 with poor 
documentationb 
DSTL: Defence Science and Technology Laboratory.
Figure 2
Diagnosis by gold standard (Ebola virus PCR) in study 
participants for the DSTL rapid diagnostic antigen test for 
Ebola virus disease, Sierra Leone, January–February 2015 
(n = 131)*
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for a CT score of 8 or above. A specificity of 99% (95% 
CI: 95.3–100.0) was achievable if an RDT score above 
CT8 was 
The positive predictive value (PPV) of the DSTL EVD 
RDT, for the study population EVD prevalence of 11.5%, 
was 79.0% (95% CI: 54.4–93.8) for a CT score of 6 and 
above and increased at higher CT score thresholds for 
a positive result (Table 3). A negative predictive value 
of 100% was achievable if a CT score 2 and above, a 
CT score 4 and above, or a CT score 6 and above, were 
classified as a positive result.
Discussion
Our data suggest that the DSTL EVD RDT is highly sen-
sitive, specific and performs well in an operational set-
ting. A high sensitivity is critical to EVD diagnostic test 
acceptability. A highly sensitive screening test such as 
this would allow high-risk suspected EVD cases to be 
prioritised for isolation and confirmatory diagnostic 
testing with RT-PCR, reducing non-EVD admissions in 
EHUs. If the sensitivity was lower, EVD-positive cases 
could be inappropriately discharged to inpatient wards, 
with risks of onward nosocomial transmission.
Although the specificity was high, a small number of 
non-EVD patients tested positive with the RDT at all T 
Line scores. Using the DSTL EVD RDT as a ‘rule-in’ test 
for EVD would result in some EVD-negative patients 
being inappropriately referred to ETCs and exposed to 
nosocomial risk, unless confirmatory testing by RT-PCR 
was undertaken.
Therefore the RDT may be best used as a ‘rule-out’ 
screening test. If the high sensitivity of the RDT is con-
firmed by further evaluation, this would allow RDT-
negative patients to be discharged, reducing pressure 
on isolation unit beds and diagnostic laboratories. 
It would allow safe and rapid referral of sick, RDT-
negative patients to general wards to receive appropri-
ate healthcare, or for patients with milder illness to be 
discharged. In addition, emergency surgical procedures 
and obstetric deliveries could be performed without 
EVD transmission risk, following a negative RDT. This 
would allow healthcare workers to confidently and 
safely treat non-EVD conditions without being exposed 
to potentially infectious patients and may allow normal 
healthcare services to be maintained in future epidem-
ics. This has been a significant challenge during the 
current epidemic [11]. Those with a positive RDT should 
be considered high-probability suspected EVD cases, 
prioritised for isolation in the appropriate risk-strati-
fied area of the EHU, with confirmatory diagnostic test-
ing performed by RT-PCR.
Our results, particularly if confirmed by larger stud-
ies on stored samples, support the use of this test for 
screening purposes. 
Limitations
The number of admissions in the study period was 
lower than expected and the EVD prevalence lower 
than that observed in late 2014, reducing the power 
of the study. In addition, it was intended that all con-
secutive EHU admissions should be recruited at study 
sites. This was not always possible as a limited num-
ber of trained staff were available to enter the EHUs to 
enrol patients and some patients were unable to give 
informed consent. However, at Connaught Hospital 
EHU, the main site of enrolment, the majority (83%) of 
admissions were enrolled. The wide confidence inter-
vals around sensitivity will need further confirmatory 
work before routine clinical use.
RDT result RDT test (T) line score
C CT CT2 CT4 CT6 CT8 CT10
EVD PCR-positive (n) 0 15 0 0 4 5 6
EVD PCR-negative (n) 107 9 1 4 2 1 1
DSTL: Defence Science and Technology Laboratory; EVD: Ebola virus disease; RDT: rapid diagnostic antigen test.
Table 1
Results of DSTL rapid diagnostic antigen test for Ebola virus disease, Sierra Leone, January–February 2015 (n = 131)
DSTL: Defence Science and Technology Laboratory; EVD: Ebola 
virus disease.
Figure 3
CT scores for the DSTL rapid diagnostic antigen test for 
Ebola virus disease, Sierra Leone, January–February 2015 
(n = 24)
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The prevalence of EVD was low in our study compared 
with earlier in the outbreak, when up to 75% of admis-
sions to the Connaught Hospital EHU were EVD-positive. 
This has resulted in a relatively low PPV for the RDT. As 
the PPV only applies for a particular population preva-
lence, the performance of the test should be confirmed 
at a higher population prevalence. It is likely that the 
PPV would be higher at a higher EVD prevalence.
We compared the RDT result to gold-standard EVD 
diagnosis with RT-PCR. The WHO recommends repeat 
testing of symptomatic patients who test negative for 
EVD by RT-PCR less than three days after the onset of 
their illness, as the sensitivity of EVD RT-PCR may be 
lower early in the clinical course of EVD [4]. Our routine 
practice complied with this policy. However, it remains 
possible that we have classified some patients as 
false-positive RDTs who were infected with Ebola virus 
but had RT-PCR results below the assay detection lim-
its. If this was the case, our study underestimates the 
diagnostic accuracy of the DSTL EVD RDT. PHE has now 
moved to an alternative in-house assay which his more 
sensitive than the Altona RT-PCR and may verify the 
DSTL test results in any future work. Further study is 
required to assess the performance of the RDT early in 
the clinical course of EVD and in the EVD incubation 
period.
Relationship to other studies
The WHO approved the first RDT for use as a screening 
test for EVD (ReEBOV Antigen Rapid Test) on the basis 
of a reported sensitivity of 91.8% (95% CI: 84.5–96.8) 
and a specificity of 84.6% (95% CI: 78.8–89.4). This 
RDT was evaluated on 147 fresh venous blood and 
146 frozen plasma samples in a laboratory setting in 
Sierra Leone [12]. Performance of this test in an opera-
tional setting has not been reported. Our findings sug-
gest that the DSTL EVD RDT performs well against this 
benchmark, exceeding these reported findings in an 
operational setting.
Conclusion
The performance of the DSTL EVD RDT in this study 
strongly supports its use as a ‘rule-out’ screening test 
for EVD. Further laboratory and operational data are 
required to improve confidence and inform further on 
sensitivity and specificity in a broader setting.
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CT score Sensitivity % 95% CI
Specificity 
% 95% CI
≥ 2 100.0 78.2–100.0 92.2 85.8–96.4
≥ 4 100.0 78.2–100.0 93.1 86.9–97.0
≥ 6 100.0 78.2–100.0 96.6 91.4–99.1
≥ 8 73.3 44.9–92.2 98.3 93.9–99.8
10 40.0 16.3–67.7 99.1 95.3–100.0
CI: confidence interval; DSTL: Defence Science and Technology 
Laboratory. 
Table 2
Diagnostic accuracy of DSTL rapid diagnostic antigen 
test for Ebola virus disease compared with gold standard 
PCR, by CT score, Sierra Leone, January–February 2015 
(n = 131)
CT score PPV % 95% CI NPV % 95% CI
≥ 2 62.5 40.6–81.2 100.0 96.6–100.0
≥ 4 65.2 42.7–85.6 100.0 96.6–100.0
≥ 6 79.0 54.4–93.8 100.0 96.7–100.0
≥ 8 84.6 54.5–97.6 96.6 91.5–99.1
10 85.7 42.2–97.6 92.7 86.7–96.6
CI: confidence interval; DSTL: Defence Science and Technology 
Laboratory; NPV: negative predictive value; PPV: positive 
predictive value. 
Table 3
Positive and negative predictive values of DSTL rapid 
diagnostic antigen test for an Ebola virus disease 
prevalence of 11.5%, by CT score, Sierra Leone, January–
February 2015 (n = 131)
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*Erratum: On 12 June 2015, the x axis label in Figure 2 was 
corrected to read ‘Site of enrolment’.
References
1. World Health Organization (WHO). Ebola situation 
report - 18th March 2015. Geneva: WHO; 2015. Available 
from: http://apps.who.int/ebola/current-situation/
ebola-situation-report-18-march-2015
2. WHO Ebola Response Team. Ebola virus disease in West Africa-
-the first 9 months of the epidemic and forward projections. N 
Engl J Med. 2014;371(16):1481-95. http://dx.doi.org/10.1056/
NEJMoa1411100 PMID:25244186
3. Youkee D, Johnson O, Amardeep K, Hall A, Lado M. King’s 
Sierra Leone Partnership Ebola holding units standard 
operating procedure. Freetown: KSLP; 2014.
4. World Health Organization (WHO). Laboratory diagnosis of 
Ebola virus disease. Geneva: WHO; 2014. Available from: 
http://apps.who.int/iris/bitstream/10665/134009/1/WHO_
EVD_GUIDANCE_LAB_14.1_eng.pdf
5. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent 
M, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse 
transcription-PCR in an outbreak setting and assessment 
of patient viral load as a predictor of outcome. J Virol. 
2004;78(8):4330-41. http://dx.doi.org/10.1128/JVI.78.8.4330-
4341.2004 PMID:15047846
6. Pathmanathan I, O’Connor KA, Adams ML, Rao CY, Kilmarx 
PH, Park BJ, et al.; Centers for Disease Control and Prevention 
(CDC). Rapid assessment of Ebola infection prevention 
and control needs--six districts, Sierra Leone, October 
2014. MMWR Morb Mortal Wkly Rep. 2014;63(49):1172-4. 
PMID:25503922
7. Lucht A, Formenty P, Feldmann H, Gotz M, Leroy E, Bataboukila 
P, et al. Development of an immunofiltration-based antigen-
detection assay for rapid diagnosis of Ebola virus infection. 
J Infect Dis. 2007;196(s2) Suppl 2;S184-92. http://dx.doi.
org/10.1086/520593 PMID:17940948
8. World Health Organization (WHO). Urgently needed: rapid, 
sensitive, safe and simple Ebola diagnostic tests. Geneva: 
WHO; 2014. Available from: http://www.who.int/mediacentre/
news/ebola/18-november-2014-diagnostics/en/
9. World Health Organization (WHO). Clinical management of 
patients in the Ebola Treatment Centres and other care centres 
in Sierra Leone. December 2014. Interim emergency guidelines. 
Geveva: WHO; 2014. Available from: https://extranet.who.
int/ebolafmt/content/clinical-management-patients-ebola-
treatment-centres-and-other-care-centres-sierra-leone
10. University of Amsterdam (UOA). STARD Statement. Standards 
for the reporting of diagnostic accuracy studies. Amsterdam: 
UOA. [Accessed: 24 Feb 2015]. Available from: http://www.
stard-statement.org/
11. Jain V, Brown CS, Johnson O. Sierra Leone: the forgotten 
mortality. Glob Health Action. 2015;8(0):26757. http://dx.doi.
org/10.3402/gha.v8.26757 PMID:25669239
12. World Health Organization (WHO). WHO emergency use 
assessment and listing for Ebola virus disease IVDs. Public 
report. Product: ReEBOV™ Antigen Rapid Test Kit EUAL 
Number: EA 0011-011-00. Geneva: WHO; 2015. Available 
from: http://www.who.int/diagnostics_laboratory/
procurement/150219_reebov_antigen_rapid_test_public_
report.pdf
